May 8, 2017 Syros Announces Late-Breaking Oral Presentation on its Research Identifying Key Genes that Control the Auto-immune Response in Lupus at FOCIS Meeting
May 8, 2017 Syros Presents New Insights on Mechanism of Action of SY-1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference
May 1, 2017 Syros Participates in International Symposium to Support MDS Foundation’s Efforts to Raise Awareness of Novel Therapies in Development for MDS
Apr 27, 2017 Syros to Present on Its Pioneering Approach to Identify Novel Drug Targets Linked to Genomically Defined Subsets of Patients at IMPAKT Breast Cancer Conference
Apr 18, 2017 Syros to Present on SY-1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference
Apr 10, 2017 Syros Announces FDA Acceptance of IND to Advance SY-1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
Apr 4, 2017 Syros Presents Data at AACR Further Supporting Clinical Potential of SY-1425, Its First-in-Class Selective RARα Agonist, for Genomically Defined AML and MDS Patients
